DSM and Crucell have expanded the activities in their existing joint venture, the Percivia PER.C6 Development Center. The JV will transform from a development center into a full biopharmaceutical company for the development of PER.C6-based biobetter proteins and monoclonal antibodies as well as global licensing of the PER.C6 human cell line for production of third party monoclonal antibodies and other proteins. The JV was established in 2006 to further develop the PER.C6 cell line and provide tu...